Chardan Capital Maintains Buy Rating for uniQure: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Chardan Capital has maintained its Buy rating for uniQure (NASDAQ:QURE) but lowered its price target from $45.00 to $27.00. uniQure is a gene therapy company focused on hemophilia, Huntington's disease, and cardiovascular diseases.
June 22, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains Buy rating for uniQure (NASDAQ:QURE) and lowers price target from $45.00 to $27.00, a potential 132.59% increase from the current share price.
Chardan Capital's maintained Buy rating for uniQure indicates a positive outlook for the stock. However, the lowered price target from $45.00 to $27.00 suggests a more conservative growth expectation. The potential 132.59% increase from the current share price could positively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100